<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322594</url>
  </required_header>
  <id_info>
    <org_study_id>CD-RI-MEDI2338-1033</org_study_id>
    <secondary_id>2010-022879-54</secondary_id>
    <nct_id>NCT01322594</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to evaluate the safety and tolerability of single ascending intravenous doses
      of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease
      (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinically Significant Hematology Laboratory Results</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinically Significant Electrocardiogram Results</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinically Significant Vital Signs Results</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinically Significant Serum Chemistry Laboratory Results</measure>
    <time_frame>Days 1 - 92</time_frame>
    <description>Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity</measure>
    <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
    <description>Area under the serum concentration-time curve from time zerio to infinity of MEDI2338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point</measure>
    <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
    <description>Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibodies (ADA) to MEDI2338</measure>
    <time_frame>Days 1, 57, and 92</time_frame>
    <description>Number of participants with ADA to MEDI2338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax)</measure>
    <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
    <description>Cmax of MEDI2338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Phase Half-life (t1/2)</measure>
    <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
    <description>t1/2 of MEDI2338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
    <description>CL of MEDI2338</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>MEDI2338 10 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI2338 30 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI2338 100 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI2338 300 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI2338 1000 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI2338</intervention_name>
    <description>MEDI2338 single intravenous (IV) dose (lowest dose)</description>
    <arm_group_label>MEDI2338 10 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI2338</intervention_name>
    <description>MEDI2338 single IV dose (next highest dose)</description>
    <arm_group_label>MEDI2338 30 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI2338</intervention_name>
    <description>MEDI2338 single IV dose (next highest dose)</description>
    <arm_group_label>MEDI2338 100 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI2338</intervention_name>
    <description>MEDI2338 single IV dose (next highest dose)</description>
    <arm_group_label>MEDI2338 300 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI2338</intervention_name>
    <description>MEDI2338 single IV dose (highest dose)</description>
    <arm_group_label>MEDI2338 1000 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single IV dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 40 years at time of screening.

          -  Females of non-childbearing potential defined as surgically sterile or at least 2
             years postmenopausal.

          -  Males, unless surgically sterile, must use 2 highly effective methods of birth control
             from screening through end of trial.

          -  A diagnosis of mild to moderate COPD.

          -  Cigarette smoking history of ≥10 pack years.

          -  Ability to understand and comply with protocol requirements, instructions and
             restrictions.

          -  COPD symptoms adequately controlled on a therapeutic regimen that has not changed in
             the 4 weeks prior to screening.

        Exclusion Criteria:

          -  Current diagnosis of any respiratory condition other than COPD.

          -  Active or history of any disease or condition that would, in the opinion of the
             investigator and/or medical monitor, place the subject at an unacceptable risk to
             participate in this study.

          -  History of or suspected history of alcohol misuse or recreational substance abuse.

          -  Treatment with oral or IV corticosteroids within 8 weeks prior to screening.

          -  Concurrent enrolment in another clinical study.

          -  Receipt of any investigational drug therapy of use of any biologicals within 6 months
             prior to screening.

          -  Known history of allergy or reaction to any component of the investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Piper, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <results_first_submitted>July 19, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2013</results_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 31 participants provided written informed consent and participated in the study at 3 sites in South Africa (2 sites) and the United Kingdom (1 site) between 24Feb2011 and 25Nov2011.</recruitment_details>
      <pre_assignment_details>Eligibile participants in the 10 and 30 mg dose groups received MEDI2338 in an open-label manner. Eligible participants in the 100, 300, and 1000 dose groups were randomized in a 3:1 ratio to receive MEDI2338 or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="P2">
          <title>MEDI2338 10 MG</title>
          <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="P3">
          <title>MEDI2338 30 MG</title>
          <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="P4">
          <title>MEDI2338 100 MG</title>
          <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="P5">
          <title>MEDI2338 300 MG</title>
          <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="P6">
          <title>MEDI2338 1000 MG</title>
          <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">RANDOMIZED SUBJECTS THROUGH STUDY DAY 240-300</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B2">
          <title>MEDI2338 10 MG</title>
          <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B3">
          <title>MEDI2338 30 MG</title>
          <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B4">
          <title>MEDI2338 100 MG</title>
          <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B5">
          <title>MEDI2338 300 MG</title>
          <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B6">
          <title>MEDI2338 1000 MG</title>
          <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.0"/>
                    <measurement group_id="B2" value="57.0" spread="4.0"/>
                    <measurement group_id="B3" value="59.7" spread="11.0"/>
                    <measurement group_id="B4" value="60.3" spread="7.1"/>
                    <measurement group_id="B5" value="55.1" spread="5.3"/>
                    <measurement group_id="B6" value="60.8" spread="6.0"/>
                    <measurement group_id="B7" value="59.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of participants experiencing serious adverse events</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of participants experiencing serious adverse events</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Significant Hematology Laboratory Results</title>
        <description>Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Significant Hematology Laboratory Results</title>
          <description>Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Significant Electrocardiogram Results</title>
        <description>Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Significant Electrocardiogram Results</title>
          <description>Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Significant Vital Signs Results</title>
        <description>Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Significant Vital Signs Results</title>
          <description>Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Significant Serum Chemistry Laboratory Results</title>
        <description>Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.</description>
        <time_frame>Days 1 - 92</time_frame>
        <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Significant Serum Chemistry Laboratory Results</title>
          <description>Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.</description>
          <population>All 31 participants entered into the study received MEDI2338 or placebo and were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity</title>
        <description>Area under the serum concentration-time curve from time zerio to infinity of MEDI2338</description>
        <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity</title>
          <description>Area under the serum concentration-time curve from time zerio to infinity of MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
          <units>ng x day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27550.5" spread="8163.6"/>
                    <measurement group_id="O2" value="104751.1" spread="40826.2"/>
                    <measurement group_id="O3" value="281781.5" spread="61554.1"/>
                    <measurement group_id="O4" value="915668.6" spread="342545.7"/>
                    <measurement group_id="O5" value="3081728.5" spread="846989.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point</title>
        <description>Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338</description>
        <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point</title>
          <description>Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
          <units>ng x day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24427.8" spread="8086.4"/>
                    <measurement group_id="O2" value="87549.7" spread="31391.2"/>
                    <measurement group_id="O3" value="250155.6" spread="40613.8"/>
                    <measurement group_id="O4" value="846433.3" spread="303849.8"/>
                    <measurement group_id="O5" value="2909818.8" spread="812729.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Anti-drug Antibodies (ADA) to MEDI2338</title>
        <description>Number of participants with ADA to MEDI2338</description>
        <time_frame>Days 1, 57, and 92</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the analysis of ADA</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-drug Antibodies (ADA) to MEDI2338</title>
          <description>Number of participants with ADA to MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the analysis of ADA</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Concentration (Cmax)</title>
        <description>Cmax of MEDI2338</description>
        <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Concentration (Cmax)</title>
          <description>Cmax of MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2458.0" spread="589.1"/>
                    <measurement group_id="O2" value="9722.2" spread="4376.8"/>
                    <measurement group_id="O3" value="27122.6" spread="2845.9"/>
                    <measurement group_id="O4" value="106042.5" spread="23883.9"/>
                    <measurement group_id="O5" value="337004.5" spread="51793.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Phase Half-life (t1/2)</title>
        <description>t1/2 of MEDI2338</description>
        <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Phase Half-life (t1/2)</title>
          <description>t1/2 of MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.85" spread="5.30"/>
                    <measurement group_id="O2" value="40.85" spread="3.51"/>
                    <measurement group_id="O3" value="28.46" spread="3.37"/>
                    <measurement group_id="O4" value="26.76" spread="5.54"/>
                    <measurement group_id="O5" value="24.87" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL)</title>
        <description>CL of MEDI2338</description>
        <time_frame>Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)</time_frame>
        <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI2338 10 MG</title>
            <description>MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O2">
            <title>MEDI2338 30 MG</title>
            <description>MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O3">
            <title>MEDI2338 100 MG</title>
            <description>MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O4">
            <title>MEDI2338 300 MG</title>
            <description>MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O5">
            <title>MEDI2338 1000 MG</title>
            <description>MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>CL of MEDI2338</description>
          <population>Of the 31 participants who entered into the study and received MEDI2338 or placebo, 25 participants received only MEDI2338 and were included in the pharmacokinetic analysis</population>
          <units>L/Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.387" spread="0.125"/>
                    <measurement group_id="O2" value="0.312" spread="0.099"/>
                    <measurement group_id="O3" value="0.365" spread="0.071"/>
                    <measurement group_id="O4" value="0.360" spread="0.110"/>
                    <measurement group_id="O5" value="0.346" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1-92</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>MEDI2338 10 MG</title>
        </group>
        <group group_id="E3">
          <title>MEDI2338 30 MG</title>
        </group>
        <group group_id="E4">
          <title>MEDI2338 100 MG</title>
        </group>
        <group group_id="E5">
          <title>MEDI2338 300 MG</title>
        </group>
        <group group_id="E6">
          <title>MEDI2338 1000 MG</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ed Piper</name_or_title>
      <organization>MedImmune, Limited</organization>
      <phone>+44 (0) 1223 471 471</phone>
      <email>pipered@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

